Trial Profile

A Single Arm Pilot Study of Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase 0

Latest Information Update: 16 Jan 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary)
Indications Cutaneous T-cell lymphoma
Focus Therapeutic Use

Most Recent Events

13 Mar 2018 Status changed from not yet recruiting to withdrawn prior to enrolment as the company pulled durvalumab from heme malignancies
15 Jan 2018 Planned initiation date changed from 1 Jan 2018 to 1 Mar 2018.
13 Nov 2017 Planned initiation date changed from 1 Nov 2017 to 1 Jan 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com